Evidence Hub

Eosinophilic pneumonia and COVID-19 vaccination

J May, Adrian Draper, R Aul

QJM, 2022

7 citations

Abstract

We recommend continued vigilance and heightened awareness of pulmonary mimics of coronavirus disease 2019 and potential rare sequelae of vaccination. Bronchoalveolar lavage may be useful for full evaluation. The vaccination programme has been the key in controlling the COVID pandemic and is both efficacious and safe.1 Rare neurological and haematological complications have been described with these vaccinations although causality has not been proven.2,3 The reporting of potential adverse effects remains a fundamental responsibility of the medical community. We describe a case of a patient presenting with respiratory symptoms following coronavirus disease 2019 (COVID-19) vaccination. A 55-year-old female presented with 11-day history of dry cough, progressive dyspnoea and pleuritic chest pain. She had no known contact with COVID-19. She was a never smoker and had no travel history. She had no exposure to birds, dampness or asbestos. She denied symptoms of connective tissue disease. There was no relevant drug history. Seven weeks prior to the onset of symptoms she had received the first dose of the ChAdOx1 nCov-19 COVID-19 vaccine. Her temperature was 37.5°C, pulse 100/min, oxygen saturations 96% on air at rest and 92% post-exertion. She had bilateral basal end inspiratory crepitations on auscultation. Chest X-ray (CXR) demonstrated bilateral lower zone opacities. Three days after symptom onset a COVID-19 polymerase chain reaction test was negative and numerous subsequent…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free